In vitro canine distemper virus infection of canine lymphoid cells: A prelude to oncolytic therapy for lymphoma

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1579-1587

  Suter, Steven E ^a   Chein, May B ^a   Von Messling, Veronika ^b   Yip, Becky ^a   Cattaneo, Roberto ^c   Vernau, William ^a   Madewell, Bruce R ^a   London, Cheryl A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD150 ANTIGEN; ENHANCED GREEN FLUORESCENT PROTEIN; LIPOCORTIN 5; MEMBRANE COFACTOR PROTEIN; MESSENGER RNA; PROPIDIUM IODIDE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANINE DISTEMPER MORBILLIVIRUS; CELL DEATH; DOG; DOG DISEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOID CELL; LYMPHOMA; NONHODGKIN LYMPHOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TREATMENT INDICATION; VIRUS ATTENUATION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD46; APOPTOSIS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DISTEMPER VIRUS, CANINE; DOGS; FLOW CYTOMETRY; GENE EXPRESSION; GLYCOPROTEINS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOGLOBULINS; JURKAT CELLS; LYMPHOCYTES; LYMPHOMA; MEMBRANE GLYCOPROTEINS; PLASMIDS; RECEPTORS, CELL SURFACE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFECTION; VERO CELLS;

EID: 14644416551     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1944     Document Type: Article

References (59)

1. Wildner O. Oncolytic viruses as therapeutic agents. Ann Med 2001;33:291-304.
2. Zwiebel JA. Cancer gene and oncolytic virus therapy. Semin Oncol 2001;28:336-43.
3. Kirn D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001;7:781-7.
4. Tatsuo H, Ono N, Tanaka K, et al. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-7.
5. Tatsuo H, Ono N, Yanagi Y. Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Viro 2001;75: 5842-50.
6. Ono N, Tatsuo H, Tanaka K, et al. V domain of human SLAM (CDw150) is essential for its function as a measles virus receptor. J Virol 2001;75:1594-600.
7. Wang N, Morra M, Wu C, et al. CD150 is a member of a family o genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics 2001;53:382-94.
8. McQuaid S, Cosby SL. An immunohistochemical study of the distribution of the measles virus receptors, CD46 and SLAM, in normal human tissues and subacute sclerosing panencephalitis. Lab Invest 2002; 82:403-9.
9. Dorig RE, Marcil A, Chopra A, et al. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993;75:295-305.
10. Wild TF, Fayolle J, Beauverger P, et al. Measles virus fusion: role of the cysteine-rich region of the fusion glycoprotein. J Virol 1994;68:7546-8.
11. Huebner RJ, Rowe WP, Schatten WE, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956;9:1211-8.
12. Hernandez S. Observacion de un caso de enfermedad de Hodgkin, con regresion de los sitomas e infartos ganglionares, post-sarampion. Stch Cabanos Cancer 1949;8:26-31.
13. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971;2:105-6.
14. Gross S. Measles and leukaemia. Lancet 1971;1:397-8.
15. Pasquinucci G. Possible effect of measles on leukaemia. Lancet 1971;1:136.
16. Taqi AM, Abdurrahman MB, Yakubu AM, et al. Regression of Hodgkin's disease after measles. Lancet 1981;1:1112.
17. Wheelock EF, Dingle JH. Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 1964;271:645-51.
18. Grote D, Russell SJ, Cornu TI, et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001;97:3746-54.
19. Peng KW, Ahmann GJ, Pham L, et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001;98:2002-7.
20. Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 1990; 64:700-5.
21. Steplewski Z, Jeglum KA, Rosales C, et al. Canine lymphoma-associated antigens defined by murine monoclonal antibodies. Cancer Immunol Immunother 1987;24:197-201.
22. Wunderli PS, Felsburg PJ. An improved method for the isolation of enriched canine peripheral blood mononuclear cell and peripheral blood lymphocyte preparations. Vet Immunol Immunopathol 1989;20:335-44.
23. Henthorn PS, Somberg RL, Fimiani VM, et al. IL-2R γ gene microdeletion demonstrates that canine X-linked severe combined immunodeficiency is a homologue of the human disease. Genomics 1994;23:69-74.
24. Ho SN, Hunt HD, Horton RM, et al. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989;77:51-9.
25. von Messling V, Zimmer G, Herrler G, et al. The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol 2001;75:6418-27.
26. Duprex WP, McQuaid S, Hangartner L, et al. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999;73:9568-75.
27. Barry DW, Sullivan JL, Lucas SJ, et al. Acute and chronic infection of human lymphoblastoid cell lines with measles virus. J Immunol 1976;116:89-98.
28. Moro L, de Sousa Martins A, de Moraes Alves C, et al. Apoptosis in canine distemper. Arch Virol 2003;148:153-64.
29. Moro L, Martins AS, Alves CM, et al. Apoptosis in the cerebellum of dogs with distemper. J Vet Med B Infect Dis Vet Public Health 2003;50:221-5.
30. Guo A, Lu C. Canine distemper virus causes apoptosis of Vero cells. J Vet Med B Infect Dis Vet Public Health 2000;47:183-90.
31. Naniche D, Varior-Krishnan G, Cervoni F, et al. Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol 1993;67:6025-32.
32. Schneider U, von Messling V, Devaux P, et al. Efficiency of measles virus entry and dissemination through different receptors. J Virol 2002;76;7460-7.
33. Lecouturier V, Fayolle J, Caballero M, et al. Identification of two amino acids in the hemagglutinin glycoprotein of measles virus (MV) that govern hemadsorption, HeLa cell fusion, and CD46 downregulation: phenotypic markers that differentiate vaccine and wild-type MV strains. J Virol 1996;70:4200-4.
34. Liszewski MK, Post TW, Atkinson JP. Membrane cofactor protein (MCP or CD46): newest member of the regulators of complement activation gene cluster. Annu Rev Immunol 1991;9:431-55.
35. Hosokawa M, Nonaka M, Okada N, et al. Molecular cloning of guinea pig membrane cofactor protein: preferential expression in testis. J Immunol 1996;157:4946-52.
36. Mead R, Hinchliffe SJ, Morgan BP. Molecular cloning, expression and characterization of the rat analogue of human membrane cofactor protein (MCP/CD46). Immunology 1999;98:137-43.
37. Miwa T, Nonaka M, Okada N, et al. Molecular cloning of rat and mouse membrane cofactor protein (MCP, CD46): preferential expression in testis and close linkage between the mouse Mcp and Cr2 genes on distal chromosome 1. Immunogenetics 1998;48:363-71.
38. Toyomura K, Fujimura T, Murakami H, et al. Molecular cloning of a pig homologue of membrane cofactor protein (CD46). Int Immunol 1997;9:869-76.
39. Tsujimura A, Shida K, Kitamura M, et al. Molecular cloning of a murine homologue of membrane cofactor protein (CD46): preferential expression in testicular germ cells. Biochem J 1998;330:163-8.
40. Kouomou DW, Wild TF. Adaptation of wild-type measles virus to tissue culture. J Virol 2002;76:1505-9.
41. Hashimoto K, Ono N, Tatsuo H, et al. SLAM (CD150)-independent measles virus entry as revealed by recombinant virus expressing green fluorescent protein. J Virol 2002;76:6743-9.
42. Maisner A, Liszewski MK, Atkinson JP, et al. Two different cytoplasmic tails direct isoforms of the membrane cofactor protein (CD46) to the basolateral surface of Madin-Darby canine kidney cells. J Biol Chem 1996;271:18853-8.
43. Metzler AE, Krakowka S, Axthelm MK, et al. In vitro propagation of canine distemper virus: establishment of persistent infection in Vero cells. Am J Vet Res 1984;45:2211-5.
44. von Messling V, Milosevic D, Cattaneo R. Tropism illuminated: lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci U S A 2004;101:14216-21.
45. Ito M, Watanabe M, Ihara T, et al. Measles virus induces apoptotic cell death in lymphocytes activated with phorbol 12-myristate 13-acetate (PMA) plus calcium ionophore. Clin Exp Immunol 1997;108: 266-71.
46. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
47. DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001;61:7464-72.
48. Hirasawa KY, Nishikawa SG, et al. Reovirus therapy of metastatic cancer models in immune-competent mice. Proc Am Assoc Cancer Res 2001;42:2437a.
49. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000;7:867-74.
50. Rampling R, Cruickshank G, Papanastassiou V, et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther 2000;7:859-66.
51. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
52. Bucheit AD, Kumar S, Grote DM, et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003;7: 62-72.
53. Fournel-Fleury C, Magnol JP, Bricaire P, et al. Cytohistological and immunological classification of canine malignant lymphomas: comparison with human non-Hodgkin's lymphomas. J Comp Pathol 1997; 117: 35-59.
54. Kiser, HE. Neoplasms-comparative pathology in animals, plants and man. Baltimore: William and Wilkins; 1981.
55. Meuten DJ. Tumors in Domestic Animals. 4th ed. Iowa: Iowa State Press; 2002.
56. Teske E, van Heerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-8.
57. Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000;105:847-51.
58. Todo T, Rabkin SD, Sundaresan P, et al. Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum Gene Ther 1999;10: 2741-55.
59. Coffey MC, Strong JE, Forsyth PA, et al. Reovirus therapy of tumors with activated Ras pathway. Science 1998;282:1332-4.